top of page

News of Note - March 8, 2023

BULL BEAR BRES|NAHAN

Wednesday, March 8, 2023

As of -> 10:25 EET


Programming update, the delay has been delayed, back for now..



With re-globalization, not de-globalization, on the mind; initial ideas are popping up about industries and sub-sectors..


Below you’ll find S&P’s eleven basic industry groups and I’ve gone down one level into sub-sectors (you can drill down much further).. The next step, for me, is to just keep jotting down ideas for each category as they come.. 😊


Basic Materials

  • Chemicals

  • Construction Materials

  • Containers & Packaging

  • Metals & Mining

  • Paper & Forest Products

Communications

  • Telecommunication Services

  • Media & Entertainment

Consumer Discretionary

  • Automobiles & Components

  • Consumer Durables & Apparel

  • Consumer Services

  • Retailing

Consumer Staples

  • Food & Staples Retailing

  • Food, Beverage, & Tobacco

  • Household & Personal Products

Energy

  • Energy Equipment & Services

  • Oil, Gas, & Consumable Fuels

Financials

  • Banks

  • Diversified Financials

  • Insurance

Healthcare

  • Health Care Equipment & Services

  • Pharmaceuticals, Biotechnology, & Life Sciences

Industrials

  • Capital Goods

  • Commercial & Professional Services

  • Transportation

Real Estate

  • Equity Real Estate Investment Trusts (REITs)

  • Real Estate Management & Development

Technology

  • Software & Services

  • Technology Hardware & Equipment

  • Semiconductors & Semiconductor Equipment

Utilities

  • Electric Utilities

  • Gas Utilities

  • Multi-Utilities

  • Water Utilities

  • Independent Power & Renewable Electricity Producers


While yesterday I was thinking lower volumes, that idea comes with a mountain of asterisks.. Carrying generalizations across industries and sub-sectors is risky and I’m thinking, first thought this morning, that it all depends..


On volumes and pricing power, 'turns' sprang to mind – in what instances can turns increase; so higher volumes, perhaps of a smaller amounts, etc... If you’re shortening distances and ostensibly time to your end market can more categories move towards (or further towards) a ‘just in time’ model..


Along these lines how can modern technologies and practices be used to increase a sister model, made/ built to order..


Now this thought will look dramatically different across sub-sectors and geographies but it makes intuitive sense, to me at least..


Raising a question, with a reshuffling of the supply chain – I’d think someone is still going to be left with working capital piling up.. Surely not all industries/ sectors lend themselves to ‘just in time’, etc..


This sets up that near-term hazard and longer term opportunity and in the back of my head further financialization is coming to mind – coupled with all that whizz bang technology, etc..


It’s all an opportunity, yes?


Humanity *always* finds a way to progress..



X)



Initial thoughts posted yesterday:


De-globalization, not so much, we're talking re-globalization; which has me thinking about volumes and pricing power..


Perhaps we’re entering an era of lower volumes (higher interest rates lean me in this direction as well) which would level the playing field a touch – your scale comes with less benefits as you’re spending money to stand in place (assuming you participate)..


Where do we find sustainable pricing power??



😊


Br. -john




 



*PRESS RELEASES*



ADS GY

Adidas


ADIDAS RESULTS IN 2022 REFLECT GEOPOLITICAL, MACROECONOMIC, AND COMPANY-SPECIFIC CHALLENGES


Major developments FY 2022

  • Currency-neutral revenues up 1% reflecting growth in all markets except Greater China

  • Double-digit increases in North America and Latin America, EMEA up high single digits

  • Gross margin declines to 47.3% due to strong increase in supply chain costs and discounting

  • Operating profit at € 669 million, including one-off costs of € 312 million

  • Operating margin decreases to 3.0%

  • Net income (continuing operations) of € 254 million includes € 350 million one-off costs

  • Executive and Supervisory Boards propose dividend of € 0.70 per share


Outlook for FY 2023

  • Currency-neutral revenues to decline at a high-single-digit rate

  • Underlying operating profit to be around break-even level reflecting sales loss of around € 1.2 billion and corresponding negative operating profit impact of around € 500 million from potentially not selling Yeezy stock

  • Reported operating loss to be € 700 million including additional negative impact of € 500 million from potential Yeezy inventory write-off and up to € 200 million one-off costs


ADIDAS EXTENDS APPOINTMENT OF CFO HARM OHLMEYER AND ANNOUNCES CHANGES TO ITS EXECUTIVE BOARD


cc: GBL BB - GBL



EAPI FP

EUROAPI


Release

Presentation

Webcast



CP | CP CN

Canadian Pacific


CP announces ratification of new collective agreement with BLET in U.S. Midwest



HII

Huntington Ingalls Industries


HII Receives Additive Manufacturing Approval from Naval Sea Systems Command



CTVA

Corteva Agriscience


Announces Commercial Launch of Vorceed™ Enlist® Corn Products



MASI

Masimo


Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives



MEKKO FH & ADS GY

Marimekko & Adidas


Announce a new limited-edition collaboration collection



SREN SW & JPM

Swiss Re & J.P. Morgan


Swiss Re closes second alternative capital transaction with J.P. Morgan

  • Swiss Re partners with J.P. Morgan to secure USD 700 million protection for severe underwriting losses

  • The alternative capital transaction extends Swiss Re's ability to pursue growth opportunities in an attractive reinsurance market



 



[BIO]



BMRN

BioMarin


FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5



AUTL

Autolus Therapeutics


Reports Full Year 2022 Financial Results and Operational Progress



VYGR

Voyager Therapeutics


Reports Fourth Quarter and Full Year 2022 Financial and Operating Results



IDYA

IDEAYA Biosciences


Reports 2022 Financial Results and Provides Business Update



N/A

Noema Pharma


Forbion co-leads CHF 103 million investment in Noema Pharma




 



*ARTICLES, ETC.*



Evaluate


Podcast – a new audio formulation for our PD(L)anner


Merck leads the new cholesterol-lowering push


Investors await details on Protagonist’s oral interleukin win


ACC 2023 – the market tries to take Medtronic’s pulse



End Points


Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug


Gilead plans to invest $47M+ to boost its capacity in southern Ireland


California 'won't be doing business' with Walgreens after abortion pill decision, Gov. Newsom says


Bristol Myers axes German launch of new cancer drug, citing pricing hurdles



Bloomberg


Biden Administration Gets Creative on Antitrust Enforcement

  • The Transportation Department’s willingness to take a more active role in opposition to the JetBlue-Spirit deal raises a host of questions about other possible, current and past transactions.


Powell’s Comments Unleash Unsettling Volatility

  • The reaction by stocks and bonds to his remarks is more than just noise. Undue tumult increases the risk of economic and market accidents.



Stat


Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA


Biden proposes expanding Medicare drug negotiation program


In Theranos’s backyard, a health tech leader takes another crack at better blood tests

bottom of page